Sanofi (SNY) Other financing activities (2009 - 2025)
Sanofi (SNY) posted Other financing activities of -$55.9 million for Q4 2025, little changed sequentially from -$56.1 million in Q3 2025, and down 335.73% YoY from $23.7 million in Q4 2024.
Sanofi (SNY) Other financing activities (2009 - 2025) Analysis & Trends
Sanofi has reported Other financing activities for 3 years, with the latest figure at -$55.9 million in Q4 2025.
- Quarterly Other financing activities fell 335.73% year-over-year to -$55.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$165.7 million (down 347.89% YoY) and the FY2025 annual result came in at -$55.9 million, down 335.73% from the prior year.
- Other financing activities steadied at -$55.9 million in Q4 2025 per SNY's latest filing, from -$56.1 million in the prior quarter.
- Over five years, Other financing activities peaked at -$8.4 million in Q1 2025 and troughed at -$56.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -55.87 Mn |
| Dec 31, 2025 | -55.87 Mn |
| Sep 30, 2025 | -56.11 Mn |
| Sep 30, 2025 | -56.11 Mn |
| Jun 30, 2025 | -45.28 Mn |
| Jun 30, 2025 | -45.28 Mn |
| Mar 31, 2025 | -8.42 Mn |
| Mar 31, 2025 | -8.42 Mn |
| Dec 31, 2024 | -12.82 Mn |
| Dec 31, 2024 | -12.82 Mn |
| Dec 31, 2009 | 38.40 Mn |
| Dec 31, 2009 | 38.40 Mn |